To this purpose, we set up a screening platform to measure the effect of libraries of molecules on several aspects of ERα signaling (e.g., receptor stability and cell proliferation) and discovered ‘anti-estrogen-like’ activities in several FDA-approved drugs not intended for BC treatment [6–13]. The gene discussed is ESR1; the disease is breast cancer.